U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Grade 3 Cutaneous Follicular Lymphoma

MedGen UID:
272675
•Concept ID:
C1333842
•
Neoplastic Process
Synonyms: Cutaneous Large B Cell Follicular Lymphoma; Large B Cell Follicular Lymphoma of Skin; Large B Cell Follicular Lymphoma of the Skin

Definition

A cutaneous lymphoma which contains more than 15 centroblasts per 40X high-power microscopic field. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVGrade 3 Cutaneous Follicular Lymphoma

Professional guidelines

PubMed

Management of Adverse Events From the Combination of Rituximab and Lenalidomide in the Treatment of Patients With Follicular and Low-Grade Non-Hodgkin Lymphoma.
Cheson BD, Morschhauser F, Martin P
Clin Lymphoma Myeloma Leuk 2020 Sep;20(9):563-571. Epub 2020 Mar 20 doi: 10.1016/j.clml.2020.03.009. PMID: 32303486
Single centre study of using bendamustine in the treatment of B-cell malignancies.
Osmani AH, Masood N
J Pak Med Assoc 2013 Jun;63(6):702-6. PMID: 23901668

Recent clinical studies

Etiology

UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial.
Benjamin R, Jain N, Maus MV, Boissel N, Graham C, Jozwik A, Yallop D, Konopleva M, Frigault MJ, Teshima T, Kato K, Boucaud F, Balandraud S, Gianella-Borradori A, Binlich F, Marchiq I, Dupouy S, Almena-Carrasco M, Pannaux M, Fouliard S, Brissot E, Mohty M; CALM Study Group
Lancet Haematol 2022 Nov;9(11):e833-e843. Epub 2022 Oct 10 doi: 10.1016/S2352-3026(22)00245-9. PMID: 36228643
New developments in non-Hodgkin lymphoid malignancies.
Ganapathi KA, Brown LE, Prakash S, Bhargava P
Pathology 2021 Apr;53(3):349-366. Epub 2021 Mar 5 doi: 10.1016/j.pathol.2021.01.002. PMID: 33685720
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.
Leonard JP, Trneny M, Izutsu K, Fowler NH, Hong X, Zhu J, Zhang H, Offner F, Scheliga A, Nowakowski GS, Pinto A, Re F, Fogliatto LM, Scheinberg P, Flinn IW, Moreira C, Cabeçadas J, Liu D, Kalambakas S, Fustier P, Wu C, Gribben JG; AUGMENT Trial Investigators
J Clin Oncol 2019 May 10;37(14):1188-1199. Epub 2019 Mar 21 doi: 10.1200/JCO.19.00010. PMID: 30897038Free PMC Article
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Daguindau N, Le Gouill S, Pica GM, Martin Garcia-Sancho A, López-Guillermo A, Larouche JF, Ando K, Gomes da Silva M, André M, Zachée P, Sehn LH, Tobinai K, Cartron G, Liu D, Wang J, Xerri L, Salles GA; RELEVANCE Trial Investigators
N Engl J Med 2018 Sep 6;379(10):934-947. doi: 10.1056/NEJMoa1805104. PMID: 30184451Free PMC Article
Outcomes of radiation therapy of indolent cutaneous B-cell lymphomas and literature review.
Gauci ML, Quero L, Ram-Wolff C, Guillerm S, M'Barek B, Lebbé C, Bagot M, Hennequin C
J Eur Acad Dermatol Venereol 2018 Oct;32(10):1668-1673. Epub 2018 May 18 doi: 10.1111/jdv.14972. PMID: 29578630

Diagnosis

Concurrent Presentation of Mycosis Fungoides and Primary Cutaneous Marginal Zone LPD: Clinicopathological Study of 4 Cases and Literature Review.
Prieto-Torres L, Machan S, Haro R, Cerroni L, Requena L, Rodríguez-Pinilla SM
Am J Dermatopathol 2023 Mar 1;45(3):163-169. Epub 2023 Jan 10 doi: 10.1097/DAD.0000000000002378. PMID: 36728288
New developments in non-Hodgkin lymphoid malignancies.
Ganapathi KA, Brown LE, Prakash S, Bhargava P
Pathology 2021 Apr;53(3):349-366. Epub 2021 Mar 5 doi: 10.1016/j.pathol.2021.01.002. PMID: 33685720
Multiple primary malignancies associated with a germline SMARCB1 pathogenic variant.
Eelloo JA, Smith MJ, Bowers NL, Ealing J, Hulse P, Wylie JP, Shenjere P, Clarke NW, Soh C, Whitehouse RW, Jones M, Duff C, Freemont A, Gareth Evans D
Fam Cancer 2019 Oct;18(4):445-449. doi: 10.1007/s10689-019-00138-4. PMID: 31240424
Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network.
Laurent C, Baron M, Amara N, Haioun C, Dandoit M, Maynadié M, Parrens M, Vergier B, Copie-Bergman C, Fabiani B, Traverse-Glehen A, Brousse N, Copin MC, Tas P, Petrella T, Rousselet MC, Brière J, Charlotte F, Chassagne-Clement C, Rousset T, Xerri L, Moreau A, Martin A, Damotte D, Dartigues P, Soubeyran I, Peoch M, Dechelotte P, Michiels JF, de Mascarel A, Berger F, Bossard C, Arbion F, Quintin-Roué I, Picquenot JM, Patey M, Fabre B, Sevestre H, Le Naoures C, Chenard-Neu MP, Bastien C, Thiebault S, Martin L, Delage M, Filleron T, Salles G, Molina TJ, Delsol G, Brousset P, Gaulard P
J Clin Oncol 2017 Jun 20;35(18):2008-2017. Epub 2017 May 1 doi: 10.1200/JCO.2016.71.2083. PMID: 28459613
Mucocutaneous paraneoplastic syndromes associated with hematologic malignancies.
Steele HA, George BJ
Oncology (Williston Park) 2011 Oct;25(11):1076-83. PMID: 22106561

Therapy

UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial.
Benjamin R, Jain N, Maus MV, Boissel N, Graham C, Jozwik A, Yallop D, Konopleva M, Frigault MJ, Teshima T, Kato K, Boucaud F, Balandraud S, Gianella-Borradori A, Binlich F, Marchiq I, Dupouy S, Almena-Carrasco M, Pannaux M, Fouliard S, Brissot E, Mohty M; CALM Study Group
Lancet Haematol 2022 Nov;9(11):e833-e843. Epub 2022 Oct 10 doi: 10.1016/S2352-3026(22)00245-9. PMID: 36228643
Management of Adverse Events From the Combination of Rituximab and Lenalidomide in the Treatment of Patients With Follicular and Low-Grade Non-Hodgkin Lymphoma.
Cheson BD, Morschhauser F, Martin P
Clin Lymphoma Myeloma Leuk 2020 Sep;20(9):563-571. Epub 2020 Mar 20 doi: 10.1016/j.clml.2020.03.009. PMID: 32303486
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.
Leonard JP, Trneny M, Izutsu K, Fowler NH, Hong X, Zhu J, Zhang H, Offner F, Scheliga A, Nowakowski GS, Pinto A, Re F, Fogliatto LM, Scheinberg P, Flinn IW, Moreira C, Cabeçadas J, Liu D, Kalambakas S, Fustier P, Wu C, Gribben JG; AUGMENT Trial Investigators
J Clin Oncol 2019 May 10;37(14):1188-1199. Epub 2019 Mar 21 doi: 10.1200/JCO.19.00010. PMID: 30897038Free PMC Article
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Daguindau N, Le Gouill S, Pica GM, Martin Garcia-Sancho A, López-Guillermo A, Larouche JF, Ando K, Gomes da Silva M, André M, Zachée P, Sehn LH, Tobinai K, Cartron G, Liu D, Wang J, Xerri L, Salles GA; RELEVANCE Trial Investigators
N Engl J Med 2018 Sep 6;379(10):934-947. doi: 10.1056/NEJMoa1805104. PMID: 30184451Free PMC Article
Outcomes of radiation therapy of indolent cutaneous B-cell lymphomas and literature review.
Gauci ML, Quero L, Ram-Wolff C, Guillerm S, M'Barek B, Lebbé C, Bagot M, Hennequin C
J Eur Acad Dermatol Venereol 2018 Oct;32(10):1668-1673. Epub 2018 May 18 doi: 10.1111/jdv.14972. PMID: 29578630

Prognosis

UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial.
Benjamin R, Jain N, Maus MV, Boissel N, Graham C, Jozwik A, Yallop D, Konopleva M, Frigault MJ, Teshima T, Kato K, Boucaud F, Balandraud S, Gianella-Borradori A, Binlich F, Marchiq I, Dupouy S, Almena-Carrasco M, Pannaux M, Fouliard S, Brissot E, Mohty M; CALM Study Group
Lancet Haematol 2022 Nov;9(11):e833-e843. Epub 2022 Oct 10 doi: 10.1016/S2352-3026(22)00245-9. PMID: 36228643
Management of Adverse Events From the Combination of Rituximab and Lenalidomide in the Treatment of Patients With Follicular and Low-Grade Non-Hodgkin Lymphoma.
Cheson BD, Morschhauser F, Martin P
Clin Lymphoma Myeloma Leuk 2020 Sep;20(9):563-571. Epub 2020 Mar 20 doi: 10.1016/j.clml.2020.03.009. PMID: 32303486
Role of imaging in low-grade cutaneous B-cell lymphoma presenting in the skin.
Kheterpal MK, Dai J, Geller S, Pulitzer M, Ni A, Myskowski PL, Moskowitz A, Kim J, Hong EK, Fong S, Hoppe RT, Kim YH, Horwitz SM
J Am Acad Dermatol 2019 Oct;81(4):970-976. Epub 2019 Jan 29 doi: 10.1016/j.jaad.2019.01.037. PMID: 30703460Free PMC Article
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Daguindau N, Le Gouill S, Pica GM, Martin Garcia-Sancho A, López-Guillermo A, Larouche JF, Ando K, Gomes da Silva M, André M, Zachée P, Sehn LH, Tobinai K, Cartron G, Liu D, Wang J, Xerri L, Salles GA; RELEVANCE Trial Investigators
N Engl J Med 2018 Sep 6;379(10):934-947. doi: 10.1056/NEJMoa1805104. PMID: 30184451Free PMC Article
Outcomes of radiation therapy of indolent cutaneous B-cell lymphomas and literature review.
Gauci ML, Quero L, Ram-Wolff C, Guillerm S, M'Barek B, Lebbé C, Bagot M, Hennequin C
J Eur Acad Dermatol Venereol 2018 Oct;32(10):1668-1673. Epub 2018 May 18 doi: 10.1111/jdv.14972. PMID: 29578630

Clinical prediction guides

Management of Adverse Events From the Combination of Rituximab and Lenalidomide in the Treatment of Patients With Follicular and Low-Grade Non-Hodgkin Lymphoma.
Cheson BD, Morschhauser F, Martin P
Clin Lymphoma Myeloma Leuk 2020 Sep;20(9):563-571. Epub 2020 Mar 20 doi: 10.1016/j.clml.2020.03.009. PMID: 32303486
A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer.
Eyre TA, Collins GP, Gupta A, Coupe N, Sheikh S, Whittaker J, Wang LM, Campo L, Soilleux E, Tysoe F, Cousins R, La Thangue N, Folkes LK, Stratford MRL, Kerr D, Middleton MR
Cancer 2019 Jan 1;125(1):99-108. Epub 2018 Oct 17 doi: 10.1002/cncr.31791. PMID: 30332497
Outcomes of radiation therapy of indolent cutaneous B-cell lymphomas and literature review.
Gauci ML, Quero L, Ram-Wolff C, Guillerm S, M'Barek B, Lebbé C, Bagot M, Hennequin C
J Eur Acad Dermatol Venereol 2018 Oct;32(10):1668-1673. Epub 2018 May 18 doi: 10.1111/jdv.14972. PMID: 29578630
Clinicopathologic, immunophenotypic, and molecular cytogenetic fluorescence in situ hybridization analysis of primary and secondary cutaneous follicular lymphomas.
Kim BK, Surti U, Pandya A, Cohen J, Rabkin MS, Swerdlow SH
Am J Surg Pathol 2005 Jan;29(1):69-82. doi: 10.1097/01.pas.0000146015.22624.c7. PMID: 15613857
DAB(389)IL-2 (denileukin diftitox, ONTAK): other potential applications.
LeMaistre CF
Clin Lymphoma 2000 Nov;1 Suppl 1:S37-40. PMID: 11707862

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...